Form 4: Lemaitre Vascular Director Acquires Shares and Stock Options

Director Bridget A. Ross acquired 420 shares of common stock and 2,594 stock options in Lemaitre Vascular, Inc.

Summary

• Bridget A. Ross, a director at Lemaitre Vascular, Inc., reported a transaction on December 6, 2024.
• She acquired 420 shares of common stock at a price of $0, which appears to be a grant of restricted stock units.
• She also acquired 2,594 stock options with an exercise price of $101.12.
• The stock options vest over a three-year period, with 33 1/3% vesting on the first anniversary of the grant date and the balance vesting in equal annual installments over the remaining two years.
• The restricted stock units also vest over a three-year period, with 33 1/3% vesting on the first anniversary of the grant date and the balance vesting in equal annual installments over the remaining two years.
• Following these transactions, Ms. Ross directly owns 2,698 shares of common stock and 2,594 stock options.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally positive as it aligns director interests with shareholders. There are no negative implications.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future performance.
• The vesting schedule of the stock options and restricted stock units aligns the director's interests with the long-term success of the company.

Future Outlook

The vesting schedule of the stock options and restricted stock units suggests a long-term commitment from the director.

Industry Context

This is a routine filing related to insider transactions, which is common in publicly traded companies. It reflects the compensation structure for directors and aligns their interests with shareholders.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of compensation for directors in publicly traded companies, particularly in the medical device industry.
• The vesting schedule of three years is also a typical practice to ensure long-term alignment of interests.
• Companies like Medtronic, Boston Scientific, and Abbott also use similar compensation structures for their directors.

Stakeholder Impact

• The transaction aligns the director's interests with shareholders, as the value of the stock options and restricted stock units is tied to the company's performance.

Key Dates

Keywords

Lemaitre Vascular, Director, Stock Options, Restricted Stock Units, Share Acquisition, Insider Trading, LMAT